🟢 Tiziana Life Sciences is trading 10% up in pre-market amid XBI's 2.61% pre-market gain

Tiziana Life Sciences is trading at $1.16, up 10.44%, with the move appearing mainly sector-driven.

• No new company-specific announcement was reported on September 24, 2026.
• Its latest official update, dated September 21, said the last patient completed the Phase 2a INFORM-MS trial of intranasal foralumab.
• Biotech ETF XBI was up 2.61% pre-market, while broader U.S. index futures traded lower.